Articles tagged with Cancer Vaccines
A vaccine booster has been shown to induce a persistent immune response against lung cancer, reducing the risk of recurrence. The study found that patients who received regular recall injections experienced improved immunological memory, which can be strengthened with additional vaccinations.
A new vaccine has been developed using a pathogen-mimicking approach, combining CpG 7909 adjuvant and synthetic peptide from melanoma antigen Melan-A/MART-1. The vaccine induced strong T cell responses in all eight patients, with one order of magnitude higher than previous studies.
Cancer researchers have developed a new method to delay dendritic cell activation, extending the time when immune cells can detect and attack cancer. By using a drug that links molecules, the approach prolongs the activity of dendritic cells, which are key to cancer vaccines.
Researchers found that a cancer vaccine can stimulate the production of CTLs against specific antigens and also reactivate spontaneously produced CTL populations against multiple cancer antigens in about 10% of patients with metastatic melanoma. This non-specific process could potentially eliminate bulk of tumor cells.
A genetically engineered listeria bacteria-based vaccine has shown promising results in targeting metastatic cancer cells, inducing a strong innate and acquired immune response. The vaccine, aiming to target pancreatic and ovarian cancers, could potentially be used to prevent recurrence after surgery and chemotherapy.
A new vaccine has induced antibodies and T cells targeting a specific cancer antigen, showing promise in delaying cancer recurrence. The NY-ESO-1/ISCOMATRIXTM vaccine demonstrated stronger responses compared to placebo or NY-ESO-1 protein alone.
Researchers found that cancer tumors reduce the release of interferon gamma and expression of perforin in CD8 T cells, disabling their ability to destroy cancer cells. However, these defects can be reversed with laboratory growth using immunological factors.
Researchers have identified SSX-2, a promising target for cancer vaccines, and found that patients mount their own immunological responses against cancer cells expressing the protein. A new early-phase clinical trial is underway to assess the safety and efficacy of an SSX-2-based vaccine.